SLC5A2 and chronic kidney disease: CKD progression in T2D is driven by the combined effects of metabolic,hemodynamic, and inflammatory and fibrotic factors.67,71,72 SGLT2 inhibitors act onmetabolic, hemodynamic, and likely inflammatory pathways, and GLP-1RAs act onthe metabolic pathway; however, finerenone is believed to actspecifically on inflammation and fibrosis by blockingoveractivation of MR.68,111,123 Clinical data suggest that finerenone may offercardiorenal benefits in patients with T2D and eGFR ≥25 mL/min/1.73 m2with proteinuria (see Question 5).8,19